NEW YORK, July 19, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court; further details about the cases can be found at the links
provided.
Fluor Corporation (NYSE:FLR)
Class Period: August 14, 2013 - May 3, 2018
Lead Plaintiff Deadline: July 24, 2018
According to the complaint, throughout the Class Period Fluor made false and/or misleading statements and/or
failed to disclose that Fluor’s bidding process for projects related to the construction of gas-fired power generation facilities
was flawed; Fluor had improperly estimated the gas-fire projects; as a result, Fluor would face craft productivity issues,
equipment issues and other execution issues; Fluor would incur multiple charges impacting quarterly results; and Fluor would
ultimately decide to discontinue the pursuit of the gas-fired power market.
To learn more about the Fluor class action go to: http://www.zlk.com/pslra-d/fluor-class-action?wire=3.
Unum Group (NYSE:UNM)
Class Period: January 31, 2018 - May 2, 2018
Lead Plaintiff Deadline: August 13, 2018
The complaint alleges that the Company was experiencing a higher claims incidence for its long-term care
business; the Company was experiencing less favorable policy terminations in connection with its long-term care business; as such,
the Company’s long-term care business loss ratio would reach the upper 90% range; and as a result of the foregoing, Defendants’
statements about Unum’s business, operations, and prospects, including statements related to the Company’s long-term care reserves
and capital management plans, were materially false and/or misleading and/or lacked a reasonable basis.
To learn more about the Unum class action go to: http://www.zlk.com/pslra-d/unum-group-2?wire=3.
Flex Pharma, Inc. (NASDAQ:FLKS)
Class Period: November 6, 2017 - June 12, 2018
Lead Plaintiff Deadline: August 20, 2018
During the class period, Flex Pharma overstated the viability and approval prospects for its product candidate
FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and as a result, Flex Pharma's public
statements were materially false and misleading at all relevant times. On June 13, 2018, Flex announced that it planned to halt its
FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its
organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic
alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or
75.12%, to close at $1.04 on June 13, 2018.
To learn more about the Flex class action go to: http://www.zlk.com/pslra-d/flex-pharma-inc?wire=3.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to
share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered
hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
